Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2025-07-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision for a paid-in capital increase (유상증자결정) and its subsequent amendment (정정신고). This type of filing is a standard regulatory disclosure in the Korean market (DART system) concerning capital structure changes, specifically share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate category for announcements regarding new share issues and capital changes.
2025-07-25 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed by Adbiotech Co., Ltd. It details the amendment of a previous capital increase filing, including changes to the third-party allocation target, payment schedule, and the resulting change in the company's largest shareholder. This document is a regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-07-25 Korean
[기재정정]경영권변경등에관한계약체결
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Change in Management Control' (경영권 변경 등에 관한 계약 체결). It details the change of the acquirer from a corporate entity to an individual and updates the payment schedule and terms for the associated third-party capital increase. Since this is a formal regulatory announcement regarding a change in control and capital structure, it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies a full takeover/merger) or Share Issue (which is a component of this, but not the primary purpose of the filing).
2025-07-25 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders). It details the rescheduling of an Extraordinary General Meeting (EGM), including the agenda items (appointment of outside directors and changes to business purposes). While it relates to a shareholder meeting, it is a formal notice of the meeting's logistics and agenda rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI). In the context of Korean regulatory filings (DART/KIND), this is a standard 'Notice of General Meeting' filing, which falls under the 'Regulatory Filings' (RNS) category as it is a formal corporate announcement of a meeting event.
2025-07-21 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Extraordinary General Meeting' (임시주주총회 소집공고) for the company 'AdBiotech'. It includes details about the meeting date, location, agenda items (such as the appointment of directors and amendments to the articles of incorporation), and information regarding shareholder voting rights. This document is a formal notice sent to shareholders to provide information and request their participation/votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2025-07-21 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the amendment of payment dates, share issuance, and the resulting change in the company's largest shareholder. This falls under the category of capital structure changes and financing activities, which is classified as 'CAP'.
2025-07-21 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.